Logo image of EQOS

EQONEX LTD (EQOS) Stock Fundamental Analysis

NASDAQ:EQOS - Nasdaq - SGXZ53262598 - Common Stock - Currency: USD

0.0931  -0.05 (-33.88%)

After market: 0.0869 -0.01 (-6.66%)

Fundamental Rating

2

Taking everything into account, EQOS scores 2 out of 10 in our fundamental rating. EQOS was compared to 231 industry peers in the Capital Markets industry. Both the profitability and financial health of EQOS have multiple concerns. EQOS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

EQOS had negative earnings in the past year.
In the past year EQOS has reported a negative cash flow from operations.
EQOS Yearly Net Income VS EBIT VS OCF VS FCFEQOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 0 -20M -40M -60M

1.2 Ratios

EQOS's Return On Assets of -122.39% is on the low side compared to the rest of the industry. EQOS is outperformed by 98.06% of its industry peers.
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EQOS Yearly ROA, ROE, ROICEQOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 0 -500 -1K -1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EQOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EQOS Yearly Profit, Operating, Gross MarginsEQOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 0 1K -1K

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for EQOS has been increased compared to 1 year ago.
EQOS has a worse debt/assets ratio than last year.
EQOS Yearly Shares OutstandingEQOS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
EQOS Yearly Total Debt VS Total AssetsEQOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 20M 40M 60M

2.2 Solvency

EQOS has an Altman-Z score of -11.66. This is a bad value and indicates that EQOS is not financially healthy and even has some risk of bankruptcy.
With a decent Altman-Z score value of -11.66, EQOS is doing good in the industry, outperforming 76.21% of the companies in the same industry.
A Debt/Equity ratio of 1.65 is on the high side and indicates that EQOS has dependencies on debt financing.
EQOS has a Debt to Equity ratio of 1.65. This is amonst the worse of the industry: EQOS underperforms 82.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Altman-Z -11.66
ROIC/WACCN/A
WACCN/A
EQOS Yearly LT Debt VS Equity VS FCFEQOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 20M -20M 40M -40M

2.3 Liquidity

EQOS has a Current Ratio of 1.08. This is a normal value and indicates that EQOS is financially healthy and should not expect problems in meeting its short term obligations.
With an excellent Current ratio value of 1.08, EQOS belongs to the best of the industry, outperforming 80.58% of the companies in the same industry.
A Quick Ratio of 1.08 indicates that EQOS should not have too much problems paying its short term obligations.
EQOS has a better Quick ratio (1.08) than 81.55% of its industry peers.
Industry RankSector Rank
Current Ratio 1.08
Quick Ratio 1.08
EQOS Yearly Current Assets VS Current LiabilitesEQOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 10M 20M 30M 40M 50M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for EQOS have decreased strongly by -1533.22% in the last year.
Looking at the last year, EQOS shows a very strong growth in Revenue. The Revenue has grown by 1741.83%.
Measured over the past years, EQOS shows a very strong growth in Revenue. The Revenue has been growing by 77.30% on average per year.
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

EQOS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.42% yearly.
EQOS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 52.26% yearly.
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EQOS Yearly Revenue VS EstimatesEQOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M
EQOS Yearly EPS VS EstimatesEQOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6 -0.8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EQOS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year EQOS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EQOS Price Earnings VS Forward Price EarningsEQOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EQOS Per share dataEQOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as EQOS's earnings are expected to grow with 25.60% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.05%
EPS Next 3Y25.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EQOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EQONEX LTD

NASDAQ:EQOS (11/29/2022, 8:00:01 PM)

After market: 0.0869 -0.01 (-6.66%)

0.0931

-0.05 (-33.88%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)09-06 2022-09-06/bmo
Earnings (Next)N/A N/A
Inst Owners0%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap4.31M
Analysts45.71
Price Target5.36 (5657.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.81
P/FCF N/A
P/OCF N/A
P/B 1.05
P/tB 1.49
EV/EBITDA N/A
EPS(TTM)-1.85
EYN/A
EPS(NY)-0.35
Fwd EYN/A
FCF(TTM)-1.08
FCFYN/A
OCF(TTM)-0.92
OCFYN/A
SpS0.11
BVpS0.09
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -122.39%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.65
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 134.1%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.08
Quick Ratio 1.08
Altman-Z -11.66
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.77%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1533.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3194.97%
EPS Next Y63.76%
EPS Next 2Y41.05%
EPS Next 3Y25.6%
EPS Next 5Y18.42%
Revenue 1Y (TTM)1741.83%
Revenue growth 3Y77.3%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-41.3%
Revenue Next 2Y31.89%
Revenue Next 3Y44.66%
Revenue Next 5Y52.26%
EBIT growth 1Y-4878.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.84%
EBIT Next 3Y48.54%
EBIT Next 5Y50.96%
FCF growth 1Y-4716.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3996.89%
OCF growth 3YN/A
OCF growth 5YN/A